Loading...
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term tolerability and toxicity, which interfere with continuous use. Umbralisib, a dual inhibitor of PI3Kδ/casein...
Saved in:
| Published in: | J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Wolters Kluwer Health
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8148421/ https://ncbi.nlm.nih.gov/pubmed/33683917 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.03433 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|